Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures

NCT00678587 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00678587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00678587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
October 31, 2009
Enrollment
292 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

chronic liver disease, hbv, hcv, hepatitis b virus, hepatitis c virus, hiv infection, human immunodeficiency virus, liver diseases, nash - nonalcoholic steatohepatitis, non-alcoholic steatohepatitis, thrombocytopenia